Of 221 DLBCL patients, 138 (62.4%) were categorized as low CD68 expression (CD68 + cells<33/HPF) and 83 (37.6%) as high CD68 expression (CD68 + cells≥33/HPF) (Fig. 1a, b), 121 (54.8%) were categorized as low CD163 expression (CD163 + cells<19/HPF) and 100 (45.2%) as high CD163 expression (CD163 + cells≥19/HPF) (Fig. 1c, d). The gene discussed is CD163; the disease is diffuse large B-cell lymphoma.